{
    "clinical_study": {
        "@rank": "111148", 
        "brief_summary": {
            "textblock": "To evaluate pyrimethamine as a prophylactic agent against toxoplasmic encephalitis in\n      individuals who are coinfected with HIV and latent Toxoplasma gondii.\n\n      Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard\n      treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine.\n      Continuous treatment is necessary to prevent recurrence of the disease, but constant use of\n      pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be\n      effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates\n      pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91\n      amendment, clindamycin arm was discontinued)."
        }, 
        "brief_title": "A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection", 
        "completion_date": {
            "#text": "March 1992", 
            "@type": "Actual"
        }, 
        "condition": [
            "Toxoplasmosis, Cerebral", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Encephalitis", 
                "Toxoplasmosis", 
                "Toxoplasmosis, Cerebral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard\n      treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine.\n      Continuous treatment is necessary to prevent recurrence of the disease, but constant use of\n      pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be\n      effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates\n      pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91\n      amendment, clindamycin arm was discontinued).\n\n      Patients are randomized to receive pyrimethamine or placebo  three times a week. All\n      patients must be on aerosolized pentamidine, trimethoprim / sulfamethoxazole (T/S), or\n      dapsone for Pneumocystis carinii pneumonia prophylaxis. Patients will be evaluated bi-weekly\n      for the first month and every other month thereafter for at least 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Prophylactic treatment for Pneumocystis carinii pneumonia with aerosolized\n             pentamidine, dapsone, or trimethoprim / sulfamethoxazole.\n\n        Allowed:\n\n          -  Most medications not specifically excluded.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Antivirals.\n\n          -  Antiretrovirals.\n\n        Patients:\n\n          -  Must be HIV positive or have an AIDS-defining illness OR be at known risk for HIV\n             infection and have a CD4 cell count < 200/mm3 and no other known immunosuppressive\n             disease.\n\n          -  Must have positive titer for Toxoplasma gondii.\n\n          -  Must be or become a patient of a CPCRA physician.\n\n          -  May participate in other clinical trials as long as there is no potential activity\n             against Toxoplasma gondii or cross-toxicity among study drugs.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  History of ocular, pulmonary, or central nervous system (CNS) toxicity.\n\n          -  CNS lesions.\n\n          -  Neurologic deficits except peripheral neuropathy.\n\n          -  Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea\n             and/or vomiting.\n\n          -  Sensitivity to pyrimethamine.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  On-going therapy with clindamycin, fansidar, methotrexate, trimetrexate, spiramycin,\n             azithromycin, clarithromycin, 566C80, and/or sulfa agents other than anti-PCP agents.\n\n        Patients with the following are excluded:\n\n          -  History of ocular, pulmonary, or central nervous system (CNS) toxicity.\n\n          -  CNS lesions or history of CNS lesions.\n\n          -  Neurologic deficits except peripheral neuropathy.\n\n          -  Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea\n             and/or vomiting.\n\n          -  Sensitivity to pyrimethamine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "600", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000666", 
            "org_study_id": "CPCRA 001"
        }, 
        "intervention": {
            "intervention_name": "Pyrimethamine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pyrimethamine"
        }, 
        "keyword": [
            "Toxoplasmosis", 
            "AIDS-Related Opportunistic Infections", 
            "Pyrimethamine", 
            "Drug Evaluation", 
            "Encephalitis", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "October 26, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Community Consortium of San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "802044507"
                    }, 
                    "name": "Denver CPCRA / Denver Public Hlth"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }, 
                    "name": "Hill Health Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19899"
                    }, 
                    "name": "Wilmington Hosp / Med Ctr of Delaware"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "AIDS Research Alliance - Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Comprehensive AIDS Alliance of Detroit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "071032842"
                    }, 
                    "name": "North Jersey Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10456"
                    }, 
                    "name": "Bronx Lebanon Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11201"
                    }, 
                    "name": "Addiction Research and Treatment Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10037"
                    }, 
                    "name": "Harlem AIDS Treatment Group / Harlem Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Clinical Directors Network of Region II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "972109951"
                    }, 
                    "name": "Portland Veterans Adm Med Ctr / Rsch & Education Grp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Richmond AIDS Consortium"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection", 
        "overall_official": [
            {
                "last_name": "Jacobson M", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Besch CL", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "1676364", 
                "citation": "Jacobson MA, Besch CL, Child C, Hafner R, Muth K, Deyton L. Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):195-8."
            }, 
            {
                "PMID": "1346413", 
                "citation": "Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. Lancet. 1992 Feb 8;339(8789):333-4."
            }, 
            {
                "PMID": "8106772", 
                "citation": "Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994 Feb;169(2):384-94."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000666"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Intervention Model: Parallel Assignment, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "AIDS Research Alliance - Chicago": "41.878 -87.63", 
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Addiction Research and Treatment Corp": "40.653 -73.959", 
        "Bronx Lebanon Hosp Ctr": "40.85 -73.867", 
        "Clinical Directors Network of Region II": "40.714 -74.006", 
        "Community Consortium of San Francisco": "37.775 -122.419", 
        "Comprehensive AIDS Alliance of Detroit": "42.331 -83.046", 
        "Denver CPCRA / Denver Public Hlth": "39.739 -104.985", 
        "Harlem AIDS Treatment Group / Harlem Hosp Ctr": "40.714 -74.006", 
        "Henry Ford Hosp": "42.331 -83.046", 
        "Hill Health Corp": "41.308 -72.928", 
        "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med": "29.951 -90.072", 
        "North Jersey Community Research Initiative": "40.736 -74.172", 
        "Portland Veterans Adm Med Ctr / Rsch & Education Grp": "45.523 -122.676", 
        "Richmond AIDS Consortium": "37.541 -77.436", 
        "Wilmington Hosp / Med Ctr of Delaware": "39.746 -75.547"
    }
}